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Abstract
This paper investigates the determinants of regional variations in
outpatient antibiotic consumption using Swiss data. The analysis con-
tributes to the debate on appropriate antibiotic use by improving the
understanding of its determinants, and may help to define more eﬀec-
tive health care policies to reduce the resistance phenomenon. Find-
ings suggest that Switzerland exhibits relatively low levels of consump-
tion among European countries. There are significant diﬀerences be-
tween cantons both in the per capita antibiotic sales and Defined Daily
Doses per 1000 inhabitants per day (DID). Econometric estimations
suggest that per capita income, demographic factors, and the density
of medical practices, are significantly related to antibiotic consump-
tion. The incidence of bacterial infections is ambigouous. Appropri-
ate policies aﬀecting antibiotic consumption in the community can be
designed by looking at crucial determinants in the model and their
relative impact.
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1 Introduction
The consumption of antibiotics has rapidly increased during the past 50 years.
Antibiotics have significantly contributed to the reduction in the likelihood of
dying from infectious diseases worldwide (WHO, 2000; 2001). However, re-
searchers suggest that almost one third of drug prescriptions are questionable
(Wise et al., 1998; Homer et al., 2000).
During the 90s, the USA experienced an increase in the use of broad spec-
trum antibiotics and prescriptions of antibiotics for common viral diseases
such as upper respiratory tract infections (Steinman et al., 2003). McCaig et
al. (2003) reports that total antibiotic prescriptions in ambulatory care fell
to 126 millions in 2000 from 151 millions in 1992. This means that 45% of the
population received antibiotics in 2000. According to Cantrell et al. (2002)
antibiotic prescription rates for people with colds, URIs, and acute bronchi-
tis was 46%, 47%, and 60% in 1996. Their analysis shows that around 11
millions of prescriptions in the USA are inappropriate and estimate a waste
of health care resources up to $ 281 millions.
Antibiotic consumption may not be optimal because of multiple market
imperfections. First, patients may not face the marginal cost of drugs when
making their consumption choices. Consumers have an incentive to pur-
chase more drugs than they would if insurance was not available (Newhouse,
1993). Second, the individual production function of health is characterized
by uncertainty. Although antibiotics are not eﬀective in treatments of viral
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diseases, patients’ lack of knowledge and experience may increase inappro-
priate consumption. Indeed, studies have shown that doctors decisions to
prescribe antimicrobials are related to patients’ expectations. Under time
pressure, doctors tend to satisfy their patients and to avoid follow up visits
(Butler et al., 1998). Third, marginal social benefits from consumption may
not reflect marginal private benefits. Marginal private benefits from con-
sumption may not internalize external benefits derived from one’s treatment
with antibiotics which reduces the probability of infection spreading to other
individuals (Elbasha, 2003). Finally, over consumption of antibiotics may
contribute to the selection of resistant bacteria, and hence, reduce their ef-
fectiveness (McGowan, 2001). Marginal social costs of antibiotic usage may
then not reflect marginal private costs since the latter do not consider the
costs of reduced antibiotic eﬀectiveness due to bacterial resistance (Levy,
1998 ; Coast et al., 1998). Because of resistance, antibiotics become a scarce
resource and it is in the interest of the society as a whole to preserve their ef-
fectiveness (Laxminarayan andWeitzman, 2002; Rowthorn and Brown, 2003;
Rudholm, 2002).
The investigation of regional variations in antibiotic consumption may
contribute to the debate on appropriate antibiotic use by improving the un-
derstanding of its determinants. Moreover, the analysis may help to define
more eﬀective health care policies to reduce the resistance phenomenon.
Diﬀerences between geographical areas may be explained by demographic,
cultural, and socioeconomic factors. However, it is hard to believe that physi-
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cians and/or patients in diﬀerent areas will not vary in their preferred treat-
ment practices for health conditions where alternative treatments are avail-
able and where the nature of the infection exhibits substantial uncertainty.
Researchers suggest that the investigation of small geographical areas may
bring out the role of health care supply organizational factors compared to
demand variables (Wennberg and Gittelsohn, 1982).
The literature lacks empirical investigation of within country variations
in antibiotic consumption. Moreover, studies focusing on international com-
parisons between countries use a descriptive statistics approach rather than
applying econometric techniques to explain the determinants of cross-country
variations (Bremon et al. 2000).
The paper intends to investigate regional variations in outpatient antibi-
otic use in Switzerland, to estimate the cantonal demand for antibiotics and
study the impact of critical factors. In section 2 we compare outpatient
antibiotic consumption in Switzerland with other European countries and
investigate cantonal diﬀerences within the country. In section 3 we estimate
the cantonal demand for outpatient antibiotics and discuss its determinants.
Section 4 concludes.
2 Variations in antibiotic consumption
2.1 Outpatient antibiotic consumption in Switzerland
In this section, we investigate outpatient antibiotic consumption in Switzer-
land and compare it with consumption in other European countries. We
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consider both total consumption in terms of defined daily doses per 1000
inhabitants per day (DID)1 and sales per capita. Swiss sales data were pro-
vided by IHA-IMS Health Market Research. Defined daily doses per 1000
inhabitants daily and sales per capita were calculated using additional demo-
graphic information and WHO standard doses (we refer the reader to section
3.2 for further details on data).
Figure 1 is constructed by using data from the European Surveillance of
Antimicrobial Consumption (ESAC I) project and including new data from
Switzerland.
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Figure 1: Outpatient antibiotic use per country including Switzerland (2002).
Sources: ESAC and IHA-IMS.
Large diﬀerences in outpatient antibiotic consumption are observed across
European countries (Cars et al. 2001 ; Goossens et al., 2005). Relatively high
1The defined daily dose (DDD) measurement unit is based upon the WHO version
2003.
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consumption defined in daily doses per 1000 inhabitants per day (DID) are
observed in France, Greece, Luxembourg, Portugal, and Italy, among others.
On the contrary, Austria, Estonia, Germany, Latvia, and the Netherlands, for
instance, exhibit significantly lower values. Median European consumption of
antibiotics in ambulatory care in 2002 is 18.8 DID. The greatest consumption
(32 DID) is attained by France. Outpatient antibiotic use in Switzerland
measured in DDDs per 1000 inhabitants daily is 9 DID, below the Dutch
level of 9.8 DID.
The ranking obtained by ordering European countries as with respect
to DDDs per 1000 inhabitants per day in 2002 suggests that Switzerland is
indeed the country with the lowest antibiotic consumption in the community.
Not surprisingly, this is in accordance with the 2001 OECD statistics
suggesting that Switzerland is among countries with low consumption rates
of pharmaceuticals. Among possible explanations is the combination of or-
ganizational aspects of the health care system based upon private health
insurances and physicians’ and patients’ attitude towards the use of drugs.
The combination of deductible and direct payments may contribute to the
prevention of moral hazard behavior. Swiss physicians and patients may ei-
ther be more aware of the implications of antibiotic consumption, such as
bacterial resistance, and face tighter financial incentives. The health eco-
nomics literature suggests that pure fee-for-service payment schemes, akin
to the Swiss one, may increase the volume of services provided compared to
capitation regimes. However, the incentive to reduce workload by increasing
6
prescriptions may be lower (see Scott, 2000).
40.5% 42.5% 43.5%
8.7%
8.4% 8.9%
8.4%
8.3% 8.9%
16.8%
16.1% 14.9%
20.1%
19.7% 19.5%
0
3
6
9
12
2002 2003 2004
D
D
D
 p
er
 1
00
0 
in
ha
bi
ta
nt
s 
pe
r d
ay
Penicillins J01C Cephalosporins J01D Tetracyclines J01A Macrolides J01F
Quinolones J01M Sulfonamides J01E Others 
Figure 2: Structure of outpatient antibiotic consumption in Switzerland
(2002-2004).
As shown in figure 2, total antibiotic consumption in ambulatory care in
Switzerland has been roughly stable over the three years considered. Con-
sumption has slightly increased in 2003 (9.5 DID) but decreased in 2004 (9.3
DID).
Looking at the consumption structure, the literature suggests that there
is wide variation in the proportion of diﬀerent classes of antibiotics between
countries (Bergan, 2001; Cizman 2001). The Swiss share of quinolones is
20.1% of total consumption in 2002. Although the Swiss use of quinolones
is not far from the European average (1.8 DID against 1.4 DID), Switzer-
land uses this category of antibiotics in the community in much higher pro-
portions (the European average share of quinolones without Switzerland is
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Figure 3: Penicillins composition in Switzerland (2002).
7.3%). This implies that Switzerland uses relatively lower proportions of
others classes of antibiotics compared to European countries.
The use of penicillins has slightly increased over time (from 40.5% in
2002 to 43.5% in 2004). The Swiss consumption of penicillins is below the
European average both in terms of DID and the share on total consumption
(3.7 DID and 40.5% compared to 8.7 DID and 46.4%). Looking at penicillins
in more details, we observe that combinations with β-lactamase inhibitors
represents 63% of total consumption of penicillins (figure 3). This proportion
is similar to the proportion used in Belgium and Portugal, for instance, and
above the European average.
Similar figures can be observed for cephalosporins and macrolides. The
Swiss consumption for the former category is 0.8 DID (8.7%) whereas the
European average is 1.9 DID (10.2%). In the latter category Switzerland
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consumes 1.5 DID (16.8%) compared to the European average of 2.7 DID
(14.3%).
The ranking of Switzerland between European countries in terms of per
capita consumption for diﬀerent classes of antibiotics can then vary. Switzer-
land is 18th out of 27 European countries for the consumption of cephalospo-
rins, and the 5th less consuming country for macrolides. On the other side,
Switzerland is the 8th most consuming country of quinolones.
It worth noticing that the comparison of Swiss consumption data with
those of other European countries as well as between the European countries
of the ESAC study requires a bit of carefulness. There may be diﬀerences
related to the collection of data since not all of the countries derive data from
the same source. These may either come from the distributional channel or
the reimbursement registrations which may not perfectly match. Moreover,
outpatient antibiotic consumption may either include or exclude antibiotic
used in nursing homes. Nursing homes are generally counted in outpatient
antibiotic consumption of most European countries although for few of them
they are included in the hospital consumption.
2.2 Cantonal diﬀerences
Switzerland is a federal state made of 26 cantons. Cantons generally diﬀer
not only with respect to geographical characteristics, but also for cultural and
socioeconomic aspects of the population and the organization of the health
care system. The analysis of cantonal diﬀerences in antibiotic consumption
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may then reflect these aspects besides epidemiological ones. We investigate
cantonal antibiotic use in terms of sales (in CHF) per capita and DDDs per
1000 inhabitants daily using yearly data from 2002 to 20042.
The average cantonal expenditure in 2002 was around CHF 12 per capita
with a standard deviation of 3.72. The expenditure varies from a minimum
of CHF 6.44 to a maximum of CHF 22.63. Average per capita expenditure
has increased between 2002 and 2003 by 3.2% and decreased afterwards by
4.5%. Diﬀerences between cantons appear to be significantly large all over
the three years.
In terms of DDDs per 1000 inhabitants per day, the average cantonal
outpatient antibiotic consumption was 9 DID in 2002 (figure 4). Average
antibiotic use has slightly increased in 2003 and then reduced to 9.3 DID in
2004. Hence, average individual consumption daily has been roughly stable
over the three years. Note, however, the wide diﬀerences between cantons.
These can be summarized by the variation coeﬃcient3: 29 in 2002, 26 in
2003, and 26 in 2004. Given a minimum cantonal consumption of 4.7 DID
in 2002 (AR - Appenzell Rhodes), the highest consumption is more than 3
times greater (15.6 DID for GE - Geneva). Similar figures are observed for
2003 (min. 5.3 DID - Max. 16 DID) and 2004 (min. 5.3 DID - Max. 15.4
DID). Median values were 7.7 DID in 2002 (ZH - Zurich), 8.3 DID in 2003
2In the analysis which follows 5 small cantons have been aggregated into 2 bigger regions
(see section 3.2 for further details).
3The variation coeﬃcient is the ratio between the standard deviation and the mean
multiplied by 100.
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and 2004 (SO - Solothurn and Zurich).
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Figure 4: Outpatient antibiotic use per canton.
Although there are substantial cantonal diﬀerences in all of the three
years observed, the variation coeﬃcient indicates that diﬀerences has slightly
reduced over time. In 2003 the big majority of cantons have increased an-
tibiotic use expressed in DDDs per 1000 inhabitants daily but two cantons
(VD - Vaud and OW - Obwalden) have reduced consumption. On average,
consumption has increased by 5.6%. However, cantons such as St. Gall (SG)
and Grisons (GR) exhibit more substantial growth. The t-test on the mean
equality between 2002 and 2003 confirms that cantonal consumption has
significantly increased. In 2004 average outpatient antibiotic consumption
expressed in DID has decreased by 2.7% compared to 2003. The reduction
characterize all cantons with the exception of Zurich.
Looking more carefully at figure 4, we note that cantons with the highest
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consumption (such as Geneva, Vaud and VS - Valais) are generally located
in the South-West part of Switzerland. Conversely, cantons with the lowest
consumption are located North-East in the country.
Cantonal antibiotic consumption can be disaggregated by main antibi-
otic classes (figure 2). We summarize the following 6 categories as previously
done for the whole Switzerland: penicillins, cephalosporins, tetracyclines,
macrolides, quinolones, and sulfonamides. Cantonal diﬀerences can be ob-
served in the structure of total consumption (figure 5). The proportion of
penicillins use is between a minimum of 33.5% in Obwalden and a maxi-
mum of 44.8% in Solothurn. Macrolides range from 12.7% to 22.1% whereas
quinolones vary from 17.2% to 23.1%. Although there are clearly diﬀerences
in the cantonal consumption structure, figures suggest that within country
variations are less substantial compared to those observed across European
countries (see Goossens et al., 2005, among others). Cantonal diﬀerences in
terms of the proportion of each antibiotic category on total consumption may
be related to local variables such as the prevalence of infections, patients’ and
doctors’ preferences, pharmaceutical marketing strategies, cantonal regula-
tion, and the incidence of bacterial resistance.
3 Explaining variations
Regional variations in antibiotic consumption may be explained by a variety
of factors. Several authors have suggested that doctors’ decision to prescribe
and patients’ use of antibiotics are explained not only by clinical factors and
12
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Figure 5: Structure of antibitic consumption in the community per canton.
by diﬀerences in bacterial infections across regions. Diﬀerence in bacterial in-
fection can hardly explain variation in morbidity as large as four fold among
industrialized countries. The literature has suggested the lack of education,
physicians and patients’ expectations, uncertainty, cultural and social behav-
ior, and diﬀerences in regulatory practice, among other factors (Belongia and
Schwatz, 1998; Finch et al. 2004).
Previous studies focusing on the determinants of antibiotic consumption
have been conducted either in the form of trials or questionnaire surveys.
Mecfarlane et al. (2002) investigated the impact of patient’s information.
Their experiment showed that the distribution of information leaflets to pa-
tients not in need for antimicrobials eﬀectively reduced their use without
aﬀecting the doctor-patient relationship. Using a questionnaire survey on
22 Australian non-randomly selected general practitioners and 336 patients,
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Cockburn and Pit (1997) showed that patients expecting a medication were
nearly three times more likely to receive it compared to other patients. More-
over, patients were ten times more likely to receive a medication if practi-
tioners perceived a patient’s expectation on prescribing. Doctors’ perception
and patients’ expectations were significantly associated to each other. Webb
and Lloyd (1994) suggested that older people are more likely to be prescribed
a medication, although this result is not confirmed by Cockburn and Pit’s
study. Harbarth et al. (2002) suggested that large diﬀerences in antibiotic
consumption between France and Germany are at least partially related to
diﬀerences in the concentration of child care facilities and the use of breast
feeding between the two countries. Finally, Unsworth and Walley (2001)
showed that antibiotic prescribing is related to practice characteristics in the
British NHS. Deprived and single-handed practices tend to prescribe more
but cheap antibiotics, while dispensers and trainers, with low level of depri-
vation and early wave fundholders have lower rate of prescriptions.
One alternative approach to investigate the determinants of antibiotic
consumption is to use regional consumption data and regress them against a
set of variables suggested by the literature as plausible causal factors of the
demand for drugs. We apply this approach to regional outpatient antibiotic
consumption in Switzerland and discuss it in the following section.
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3.1 An econometric approach
From the economic point of view, antibiotics are an input of the health
care and the health production process. Therefore, following the Grossman’s
tradition it is possible to derive the demand for antibiotics directly from the
demand for health care. In this framework, the demand for antibiotics is a
demand derived from the demand for healthy days and can be specified using
the basic framework of household production theory4. In this framework, a
household combines drugs, health care, time, exercise, education and capital
equipment to produce healthy days.
Inspired by this approach and given the restriction of aggregate data5, it
is possible to specify an ad-hoc demand function for the cantonal per capita
outpatient antibiotic consumption, where the demand for antibiotics depends
on the individual’s stock of health care (H), income (Y ), prices of antibiotics
and prices of other health care services, the incidence of infectious diseases
and other socioeconomic variables such as age, nationality and education.6
These socioeconomic variables are usually included in the model as proxies for
the individual stock of health care, which is diﬃcult to measure. Moreover,
under a pure fee-for-service reimbursement scheme, there may be incentives
4For a precise presentation of the household production theory, see Becker (1975). See
also Grossman (1972) for an application of household production theory to health care.
5An alternative approach would be to use more desagreggated data even at individual
level. However, such a dataset was not available.
6Of course, we are aware that the use of aggregated data to explain individual antibi-
otics consumption implies the assumption that the hypothesized relationship between the
economic variables in question is homogeneous across all individuals. Therefore, using this
aggregate date set at the cantonal level we could encounter an aggregation bias.
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to induce the demand for physicians’ services7. Thus, the demand for antibi-
otics could also depend on some characteristics of the supply of health care
services as physicians’ density.
Taking into account the availability and the quality of data for the Swiss
cantons, we specify the following parsimonious empirical model for the per
capita demand of outpatient antibiotics:
Dit = f(Yit, Pit, Dphit,Dphait, over65it, under20it, FOit, EDUit, INF1it,
INF2it,DTt), (1)
where Dit is the per capita antibiotic consumption in canton i and quarter t,
measured in Defined Daily Doses, Yit is the cantonal per capita income, Pit is
the price of a Defined Daily Dose, Dphit is the cantonal physicians’ density,
Dphait is the cantonal pharmacies’ density, over65it indicates the percentage
of the population older than 65, under20it is the percentage of the population
below 20, FOit is the share of foreigners on total population and EDit is the
percentage of individuals without post-mandatory education. Two indicators
of infections are also included in equation (1): the number of campylobacter
infections (per 100,000 inhabitants per year) and the number of streptococcus
pneumonie infections (INF1it, INF2it). Finally, DTt is a dummy variable to
control for seasonal eﬀects of antibiotic consumption. This takes value equal
to 1 for season t (t = 1, 2, 3, 4); otherwise is 0.
Estimation of equation (1) requires the specification of a functional form.
7For a summary reading of the supply-induced demand theory see McGuire (2000).
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The log-log form oﬀers an appropriate functional form for answering ques-
tions about antibiotic consumption elasticities. The major advantage is that
the estimated coeﬃcients amount to elasticities, which are, therefore, as-
sumed to be constant. By applying the log-log functional form, the model
can be written as:
lnDit = β0 + β1 lnYit + β2 lnPit + β3 lnDphit + β4 lnDphait (2)
+β5 lnunder20it + β6 ln over65it + β7 lnFOit + β8 lnEDUit
+β9 ln INF1it + β10 ln INF2it + β11DT1 + β12DT2 + β13DT3 + εit.
As to the choice of the econometric technique, it should be noted that
in the econometric literature we find various types of models focusing on
cross-sectional variations, i.e. heterogeneity across units. The four most
widely used approaches are: the OLS model, the least squares dummy vari-
able (LSDV) model, the error components model (EC) and the Kmenta
approach8. Moreover, we should consider that our panel data set is char-
acterized by a relatively small number of time periods, a limited number
of cross-sectional units and a zero within variation for most of the explana-
tory variables. The only two variables that are changing over time are the
outpatient per capita consumption and the price of an antibiotic daily dose.
Hence LSDV and EC models are the less appropriate ones. The estimation
of equation (2) was carried out using OLS and GLS estimation procedures
8For a detailed presentation of the econometric methods that have been used to analyse
panel data, see Greene (2003).
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for pooled time-series and cross-sectional data suggested by Kmenta (1986)9.
Since many explanatory variables are repeated over time, we might have prob-
lems with the estimation of the variance of the coeﬃcients. For this reason we
estimated the model by OLS using the linearization/Huber/White/sandwich
(robust) estimates of variance. The correlation within cantons was also taken
into account by clustering the error as suggested by Roger (1993).
3.2 The data
The data for the estimation of equation (2) were obtained from three sources.
Information on the per capita income, physicians’ and pharmacies’ density,
demographic structure of the population, the share of foreign people, and
the level of education, were extracted from yearly publications by the Swiss
Federal Statistical Oﬃce. Information on the number of streptococcus pneu-
monie infections were obtained from the Swiss Federal Oﬃce of Public Health,
whereas the data on antibiotic consumption and price were obtained from
a data set created by IHA-IMS Health Market Research. The latter in-
cludes aggregate outpatient antibiotic expenditure and consumption of dif-
ferent classes of antibiotics for Switzerland. Quarterly data were available
for three years (2002-2004) and detailed at cantonal level. Five small can-
tons have been aggregated to obtain two "macro" cantons so that the total
number of cantons was reduced to 23 instead of 26.
9For a general presentation of this econometric procedure see Kmenta (1986) and
Greene (2003). The estimation has been performed using the econometric software
“Limdep8”.
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Data on antibiotic consumption derives from transactions between whole-
salers and pharmacies and physicians in Switzerland. Since the retailers’
stock of drugs is roughly constant over time, wholesales data provide a good
estimation of outpatient antibiotic consumption in the country. However,
our data may slightly underestimate final consumption for three main rea-
sons. First, data collected for ambulatory care at least partially exclude
drugs delivered in nursing home facilities10. Second, errors in data collec-
tion measurements may account for approximately 5% of the data which are
missing. Third, since the aim of our analysis is to focus on ambulatory care,
few antibiotic classes mainly related to hospital care (representing less than
2% of the data) were excluded from the purchased data set.
The data were available on a specific software, “ORACLE sales Analyser”,
having a multidimensional cube structure: the product, the region, the time
period, the channel of sales, and measures of consumption. The data set was
partially exported into MS Excel, LIMDEP and STATA8 formats to perform
the analysis.
The Anatomical Classification (AC-system) provided by the European
Pharmaceutical Market Research Association (EphMRA) classifies drugs into
16 groups at three or four levels with an alpha-numeric coding structure. All
anti-bacterial agents (antibiotics) are identified by the alpha-numeric code
J01. Antibiotics were disaggregated into diﬀerent classes (for example, J01F
10In Switzerland around 50% of nursing homes have an internal pharmacy unit. Antibi-
otics delivered by the internal pharmacy are not included in the dataset and counted as
hospital consumption.
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macrolides) to investigate the consumption structure in section 2. Because
the classification system of EphMRA does not perfectly match the interna-
tional one, we rearranged some of the classes to obtain the standard antibiotic
classes commonly used in international studies11. In particular, according to
the EphMRA classification, broad spectrum penicillins (coded J01C) and
medium and narrow spectrum penicillins (coded J01H) define two separate
groups but have been grouped together in the ATC classification (J01 C
penicillins). Quinolones are included in class M in the ATC international
classification, whereas they fill class G for EphMRA. We finally summa-
rized seven diﬀerent classes : J01 A tetracyclines, J01 C penicillins, J01 D
cephalosporins, J01 F macrolides, J01 M quinolones, J01 E sulfonamides and
others.
Consumption is measured in terms of currency units (CHF) and the num-
ber of sold packages. Furthermore, the data set provides a third measure
named Counting Units (CU). CU are defined in terms of milligrams and
days of treatment (DOT). DOT are derived from milligrams using the total
number of sold packages, the milligrams per package and the Defined Daily
Dosage (DDD) as DOT = (Number of packages)(mg. per package)/DDD.
The latter measure, according to the WHO12, is the assumed average main-
11The ATC classification used in international studies is an extension of the EphMRA
classification suggested by Norwegian researchers in the 70’s. Since 1996, the use of the
ATC and, more generally, of the ATC/DDD system is recognized by the WHO as the
international standard.
12This is a constant for each active pharmaceutical ingredient. As the WHO emphasized,
the DDD is a unit of measurement and does not necessarily reflect the recommended or
the prescribed daily dose". For example, doses may depend on individual characteristics
such as age and weight.
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tenance dose per day for a drug used for its main indication in (by) adults.
For some products like Penicillins, the standard counting unit is not the
milligrams but the International Unit (IU) established by the UK National
Institute for Medical Research. Hence, we adapted the above expression to
consider IU instead of milligrams.
In addition to the original variables we calculated total per capita sales
and days of treatment per 1000 inhabitants per day (DID) using demographic
data at cantonal level. The latter measure constitutes the explained variable
in the econometric model defined by equation (2).
Since many explanatory variables were available for 2002 only, we esti-
mated equation (2) using four quarters. As an exception, the level of educa-
tion (EDU) refers to year 2000. Table 1 gives summary statistics of variables
included in the model.
Variables Unit of measurement Min. Med. Max.
Outpatient antibiotic DDDs per 1000 4.28 7.89 18.49
consumption (DID) inhabitants per day
Income per capita (Y) Income (CHF)/pop. 35952 45746 77583
Price of a daily dose (P) Sales (CHF)/DDDs 3.40 3.72 4.32
Physicians’ density (Dph) Physicians/100000 inhab. 118 160 353
Pharmacies’ density (Dpha) Pharmacies/100000 inhab. 5 18 55
Population age over 65 (over65) Over 65/pop. 0.12 0.15 0.21
Population under 20 (under20) Under 20/pop. 0.17 0.24 0.26
Share of foreign population (FO) Foreign people/pop. 0.09 0.19 0.38
Incidence of campylobacter Number/100000 inhab. 21.5 188 908
infections (INF1)
Incidence of strep. pneumonie Number/100000 inhab. 2 25 144
infections (INF2)
Percentage of people without Basic education/pop. 0.19 0.24 0.32
post-mandatory education
Table 1: Variables notation and summary statistics
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3.3 Estimation results
The estimation of the ad-hoc demand equation specified by (2) gives satis-
factory and stable results. We summarize them in table 2, both for the OLS
and the GLS methods.
In both models the majority of the coeﬃcients are significantly diﬀerent
from zero and carry the expected sign. Moreover, diﬀerences in coeﬃcients
between the two models are relatively small. The adjusted R-squared in
the OLS estimation suggests that the model explains around 85% of total
variations.
Since per capita antibiotic consumption and regressors are in logarithm
form, the coeﬃcients can be interpreted as health expenditure elasticities.
For instance, the income elasticity of health expenditure is negative and
significantly diﬀerent from zero. This result entails that income have a sig-
nificant influence on the level of per capita antibiotic consumption. Similarly
for education, the coeﬃcient shows that an increase in the percentage of
people without post-mandatory education increases the per capita antibiotic
consumption. The impact of income and education confirm that income is
highly correlated with the level of education: the higher the level of income
and education, the lower the per capita consumption of antibiotics.
In terms of the investment in health function in the Grossman model
the results suggest that relatively rich and highly educated people either use
health care inputs (antibiotics) more eﬃciently or have higher initial health
stocks. Higher levels of productivity imply that the same amount of health
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investment can be obtained by a lower amount of health care services. Also,
higher initial health stocks imply that lower investment in health, and hence
in health care inputs, are required for any given level of optimal health stocks,
ceteris paribus.
Price of a daily dose does not have any significant impact on consump-
tion, although it exhibits the expected sign: the higher the price of a daily
dose, the lower the demand for antibiotics. The rationale for such a low level
of significance may that Swiss consumers bear only a small fraction of the to-
tal cost of drugs. Although they directly pay for antibiotic when purchasing
them, they are at least partially reimbursed afterwards by the insurance pro-
vided that total health expenditure overcomes the yearly deductible applied
in the contract. Moreover, the demand for antibiotics may be more inelastic
compared to other types of drugs since antibiotics are generally purchased
under doctor’s prescription.
Elasticities of physicians’ density show positive values. This implies that
an increase in the number of physicians at cantonal level causes an increase in
the cantonal per capita antibiotic consumption. A 10% increase in physicians’
density increases per capita daily doses approximately by 9%.
The result suggests some evidence of supply-induced demand in the Swiss
health care sector. This is in accordance with the literature suggesting that
systems where physicians are paid under a fee-for-service scheme,13 akin to
the Swiss one overconsumption of drugs is more likely. On the other side,
13For further details on the supplier induced demand theory see McGuire (2000).
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the coeﬃcient on the density of pharmacies is not significant. The rationale
may be that antibiotics can only be bought under physician’s prescription.
Elderly people are less likely to use antibiotics compared to other cat-
egories. This is suggested by the negative coeﬃcient of the percentage of
population aged over 65. The reason may be found in the fact that elderly
people living at home, and not in nursing homes, experience a low incidence
of illness. On the other side, the percentage of population aged under 20 has
a positive impact on consumption but this is not significant.
With respect to the share of foreign people on the total population, a 1%
increase is associated to 0.18%-0.20% increase in the per capita outpatient
antibiotic consumption. Cultural diﬀerences or diﬀerences in the incidence
of infectious diseases may account for this result.
Epidemiological factors such as the incidence of bacterial infections give
some ambiguous results. The incidence of campylobacter infections exhibit
the expected positive sign in all the estimations. However, the level of sig-
nificance varies with the estimated model. Surprisingly, the incidence of
streptococcus pneumonie infections has a negative impact on consumption
although the coeﬃcient is not significant in two cases. To summarize, the
estimates suggest that the incidence of infections may not have a strong im-
pact on the demand for antibiotics compared to other factors although there
is some evidence of a slightly positive eﬀect. One reason for this not so clear
evidence may be found in the reliability of data on the local incidence of
infections which are diﬃcult to measure.
24
Time dummies suggest that there are some seasonal eﬀects in antibiotic
consumption in ambulatory care. The coeﬃcient of the winter dummy, β11,
is positive and significantly diﬀerent from zero. On the other side, spring and
summer dummies are negative and significant. Hence, the hypothesis that
cantonal consumption is indeed higher in winter periods and lower in spring
and summer periods compared to autumn periods could not be rejected. This
may capture the seasonal trend in the incidence of respiratory tract infections
which aﬀects the use of antibiotics in ambulatory care.
OLS OLS corr. Robust GLS
Coeﬃcients Std. Err. Coeﬃcients Std. Err. Coeﬃcients Std.Err.
Constant -0.869 1.953 -0.868 1.784 -0.807 1.692
lnY -0.525∗∗ 0.197 -0.524∗∗ 0.073 -0.526∗∗ 0.190
lnP -0.158 0.324 -0.157 0.179 -0.211 0.163
lnDph 0.923∗∗∗ 0.116 0.923∗∗ 0.087 0.886∗∗∗ 0.076
lnDpha 0.015 0.041 0.015∗ 0.003 0.015 0.032
lnunder20 0.134 0.425 0.134 0.193 0.284 0.367
lnover65 -0.970∗∗∗ 0.292 -0.970∗ 0.207 -0.825∗∗ 0.282
lnFO 0.176∗∗ 0.065 0.176∗ 0.050 0.201∗∗ 0.066
lnEDU 0.787∗∗∗ 0.163 0.787∗ 0.203 0.690∗∗∗ 0.171
lnINF1 0.081∗ 0.033 0.081∗∗ 0.009 0.064∗∗ 0.021
lnINF2 -0.043 0.029 -0.042∗∗ 0.005 -0.039 0.027
DT1 0.070∗ 0.034 0.070∗∗∗ 0.002 0.073∗∗∗ 0.009
DT2 -0.196∗∗∗ 0.034 -0.196∗∗∗ 0.003 -0.195∗∗∗ 0.009
DT3 -0.170∗∗∗ 0.034 -0.170∗∗∗ 0.003 -0.180∗∗∗ 0.007
* signifi cant at 5% , ** signifi cant at 1% , *** sign ifi cant at 0.1% .
Table 2: Estimated coeﬃcients obtained by OLS and GLS methods.
4 Conclusions
The investigation of regional variations in outpatient antibiotic consumption
may help to understand the determinants of the demand for antibiotics and
contribute to the discussion on the reduction of antibiotic resistance. There
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is a lack of empirical evidence both in the analysis of within country and
within country variations in antibiotic consumption.
We investigated outpatient antibiotic consumption in Switzerland at can-
tonal level and by comparison with other European countries. We showed
that Switzerland uses relatively low volumes of antibiotics in ambulatory
care. In terms of consumption structure, Switzerland is characterized by
high proportions of quinolones.
Antibiotic consumption in ambulatory care has significantly increased
in terms of Defined Daily Doses per 1000 inhabitants per day (DID) and
sales per capita between 2002 and 2003 in most Swiss cantons. Conversely,
consumption has generally decreased in 2004.
The investigation of cantonal diﬀerences shows that there are wide varia-
tions across cantons. Variations are less remarkable in terms of consumption
structure.
Regional variations in outpatient antibiotic use within the country can
hardly be explained by epidemiological factors only. Multiple regressions
on quarterly data for 2002 using OLS and GLS estimators suggest that per
capita income, demographic factors, including the proportion of foreign resi-
dents, and the density of medical practices may contribute to explain cantonal
diﬀerences in antibiotic use.
More eﬀective policies to improve the eﬃcient use of antibiotics in the
community may be driven by these findings. Appropriate incentives aﬀect-
ing antibiotic consumption and hence levels of bacterial resistance can be
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designed by looking at crucial determinants suggested in the model and their
relative impact.
Econometric models using data at local level and the application of multi-
ple-choice models to selected categories of antibiotics are required to confirm
previous findings and capture the eﬀects of seasonal consumption patterns.
Additional determinants of regional diﬀerences, including endogenous bacte-
rial resistance, could be included depending on the availability of local data.
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